Study of AVZO-021 in Patients With Advanced Solid Tumors

Summary

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Solid Tumor
• HR+/HER2- Breast Cancer
• HR+, HER2-, Advanced Breast Cancer
• CCNE1 Amplification
• Epithelial Ovarian Cancer
• Primary Peritoneal Cancer
• Fallopian Tube Cancer
• Endometrial Cancer
• TNBC - Triple-Negative Breast Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Avenzo Therapeutics, Inc.

Last updated on ClinicalTrials.gov

September 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites